Destiny Pharma PLC unveils further positive results for c-difficile treatment as market research points to its commercial potential

NTCD-M3, which scientists are readying to period III clinical trials, was the subject to a different…

Summit Therapeutics PLC says c-difficile trial slowed by coronavirus pandemic disruption

US infectious ailments agency BARDA is serving to to fund the demo with a grant worthy…